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A B S T R A C T
Multiple sclerosis (MS) is a complex inﬂammatory disease of unknown etiology that affects the central
nervous system (CNS) white matter, and for which no effective cure exists. Indeed, whether the primary
event in MS pathology affects myelin or axons of the CNS remains unclear. Animal models are necessary
to identify the immunopathological mechanisms involved in MS and to develop novel therapeutic and
reparative approaches. Speciﬁcally, viral models of chronic demyelination and axonal damage have been
used to study the contribution of viruses in human MS, and they have led to important breakthroughs in
our understanding of MS pathology. The Theiler’s murine encephalomyelitis virus (TMEV) model is one
of the most commonly used MS models, although other viral models are also used, including neurotropic
strains of mouse hepatitis virus (MHV) that induce chronic inﬂammatory demyelination with similar
histological features to those observed in MS. This review will discuss the immunopathological
mechanisms involved in TMEV-induced demyelinating disease (TMEV-IDD). The TMEV model
reproduces a chronic progressive disease due to the persistence of the virus for the entire lifespan in
susceptible mice. The evolution and signiﬁcance of the axonal damage and neuroinﬂammation, the
importance of epitope spread from viral to myelin epitopes, the presence of abortive remyelination and
the existence of a brain pathology in addition to the classical spinal cord demyelination, are some of the
ﬁndings that will be discussed in the context of this TMEV-IDD model. Despite their limitations, viral
models remain an important tool to study the etiology of MS, and to understand the clinical and
pathological variability associated with this disease.
 2012 Elsevier Ltd. All rights reserved.
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Virus associated to multiple sclerosis.
Family Virus Reference
Herpesviridae Human herpes virus type 6 Knox et al. (2000)
Herpes complex virus (VHS) Perron et al. (1993)
Varicella zoster virus (VVZ) Brettschneider et al. (2009)
Epstein–Barr Virus (EBV) Lu¨nemman et al. (2010)
Marek’s disease virus (MDV) Bougiouklis (2006)
Retroviridae Human T cell leukemia
virus type 1 (HTLV-1)
Oger (2007)
Human endogenous
retrovirus
Perron et al. (2012)
Paramyxoviridae Measles virus Fujinami et al. (1983) and
Ahlgren et al. (2012)
Mumps virus Tobler et al. (1982)
Parainﬂuenza virus type 1 Rauch et al. (1975)
Canine distemper virus Haile et al. (1982)
Simian virus type 5 Goswami et al. (1984)
Coronaviridae Coronavirus Boucher et al. (2007)1. Introduction
1.1. Multiple sclerosis
Multiple sclerosis (MS) is a chronic inﬂammatory disorder of
the human central nervous system (CNS), and it is considered to be
the prototypical immune-mediated demyelinating disease. The
involvement of the immune system in the pathogenesis of MS is
irrefutable, and increased susceptibility to this disease has been
associated with major histocompatibility complex (MHC) class II.
MS is the main cause of non-traumatic neurological disability in
young adults, affecting the most productive period of their lives,
and it is characterized pathologically by focal plaques of
demyelination in the white matter of the brain and spinal cord
(Compston and Coles, 2008). Despite major advances in our
understanding of the pathophysiology of MS, its etiology remains
unknown. Most current therapies target the immune system or the
inﬂammatory process. Indeed, clinical studies have demonstrated
the therapeutic beneﬁts of immunomodulatory or immunosup-
pressive treatments in patients in the early stages of the disease,
which slow the progression of MS and the onset of permanent
disability. However, no current therapies can cure or prevent the
disease, highlighting the need for further studies to elucidate the
etiology of MS.
1.1.1. Etiological aspects
MS is generally considered an autoimmune demyelinating
disease, with inﬂammatory inﬁltrates representing a primary
pathogenic element. While its etiology remains unknown, infec-
tious agents have long been suspected as triggers of this disease
(Ascherio and Munger, 2007a; Kurtzke, 1993). Moreover, evidence
strongly suggests that myelin is targeted by an autoimmune
reaction, although this still remains unproven. Oligodendrocyte
apoptosis with microglial activation has been described in early
MS lesions, in the absence of lymphocytes or myelin phagocytosis
(Barnett and Prineas, 2004). Although inﬂammatory demyelinat-
ing lesions are a common pathological feature, the clinical course
of MS is quite variable. Accordingly, the cause of MS appears to be
multifactorial, suggesting that different etiological pathways
converge to produce similar clinical and pathological outcomes.
Epidemiological evidence suggests that MS is an environmentally
triggered disease, and several viruses have been linked with MS
pathogenesis, including human herpes virus type 6 (Tait and
Straus, 2008), Epstein–Barr virus and endogenous retrovirus
(Ascherio et al., 2001; Jilek et al., 2008; Martinez et al., 2007;
Perron and Lang, 2010; Sargsyan et al., 2010). However, none of the
viruses implicated to date (Table 1) can satisfactorily explain the
etiology of all MS cases. Genetic and environmental factors are
thought to interact to varying degrees, resulting in signiﬁcant
clinical and pathological variability (Ascherio and Munger,
2007a,b). It is generally assumed that in MS, the immune system
erroneously identiﬁes CNS myelin as foreign and thus, attempts to
destroy it. This view is supported by studies in an animal model,
experimental autoimmune encephalomyelitis (EAE) in which
immunization with myelin, myelin proteins or peptides provokes
immune-mediated destruction of CNS myelin. Although the
mechanisms of T cell-mediated myelin destruction have beenwell described in these models, the mechanism by which the
immune system identiﬁes myelin as a foreign body in MS patients
remains unknown. Imaging studies strongly suggest that MS
begins as an inﬂammatory process but later develops a neurode-
generative component, which may progress independently of
inﬂammation. An alternative view is that MS is a neurodegenera-
tive process that is exacerbated by secondary inﬂammation that
provokes demyelination. Resolving this question is critical to
understand the disease and develop new treatments that target the
underlying mechanism(s) in MS.
1.1.2. Neurodegeneration vs inﬂammation
The relationship between inﬂammation and neurodegeneration
in the different stages of MS is somewhat controversial (Lassmann,
2010; Trapp and Nave, 2008). Axonal degeneration (Ferguson et al.,
1997; Trapp et al., 1998) is now accepted as the major cause of
irreversible neurological disability in MS patients. The lack of
efﬁcacy of current anti-inﬂammatory treatments in the progres-
sive stage of MS and the low number of contrast-enhancing lesions
are generally taken as evidence that neurodegeneration exists in
the absence of inﬂammation. Although this view is partially
supported by neuropathological studies, inﬂammation has been
mainly quantiﬁed in the absence of immunocytochemistry with
speciﬁc markers for T cells, B cells and macrophages. This approach
is adequate to quantify perivascular inﬂammatory inﬁltrates but
not to evaluate diffuse inﬂammation in the tissue parenchyma.
More recently, the relationship between inﬂammation and
neurodegeneration has been addressed in a large, detailed
quantitative study of autopsy data from MS patients and controls
(Frischer et al., 2009). One of the prominent ﬁndings of this study
was that inﬂammation occurred in the brains of patients with
progressive disease, both in lesioned areas and in the apparently
healthy white matter and meninges. In general, a signiﬁcant
correlation was observed between inﬂammation and neurode-
generation in active demyelinating lesions, inactive lesions and
apparently healthy white matter. While these observations clearly
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MS, in all stages and among all lesion types, it remains unclear
whether inﬂammation is the cause or a secondary consequence of
neurodegeneration. Thus, it still remains to be proven that MS is
primarily a neurodegenerative disease with secondary inﬂamma-
tory demyelination.
1.1.3. Cortical demyelination
White matter demyelination can occur through distinct
mechanisms that have been well characterized in the literature
(Lucchinetti et al., 2000; Noseworthy et al., 2000). However, MS
lesions can also affect the gray matter (Brownell and Hughes, 1962;
Lumsden, 1970; Peterson et al., 2001). Although cortical demye-
lination was a surprise to MS community, it has been evident in the
literature for decades (Brownell and Hughes, 1962; Lumsden,
1970). Three types of cortical lesions have been described on the
basis of their location within the layers of the cortical gray matter:
type I lesions are leukocortical areas of demyelination that
contiguously occupy the subcortical white matter and cortex,
and they consist of white matter plaques that extend into the lower
layers of the cortex (Peterson et al., 2001); type II lesions are small
perivascular areas; and type III lesions are strips of demyelination
that extend from the pia, traversing several gyri to terminate in
cortical layers 3 or 4. Type III lesions are the most abundant in the
progressive stage of the disease, and while rare in acute and
relapsing MS, they are prominent in patients with primary or
secondary progressive MS (Kutzelnigg and Lassman, 2005). These
lesions are predominantly located in the insular cortex, the
frontobasal and temporobasal cortex and the gyrus cinguli
(Kutzelnigg and Lassman, 2006), although cortical demyelination
has also been described in the hippocampus and cerebellum
(Geurts et al., 2007). It remains unclear whether cortical
demyelination is mediated by immune effectors or if it compro-
mises the blood–brain barrier (BBB). Demyelination in the cortex is
associated with microglia activation, whereas T and B lymphocytes
are sparse in the cortical parenchyma. However, systematic studies
have revealed active cortical demyelination associated with
profound meningeal inﬂammation (Lucchinetti et al., 2011),
suggesting that inﬂammatory cells in the meninges produce a
soluble factor that diffuses into cortical tissue and destroys myelin
directly or indirectly via microglia activation. It is of great interest
to determine whether similar subpial cortical lesions occur in MS
models, and more importantly, how they can be induced.
1.2. Animal models of multiple sclerosis: an overview
Choosing an appropriate animal model to study a complex
disease like MS presents several challenges, mainly associated with
clinical and genetic heterogeneity. Two main animal model
systems are used to study MS: experimental autoimmune
encephalomyelitis (EAE), and experimental viral infection, com-
monly with Theiler’s murine encephalomyelitis virus (TMEV). Both
models have signiﬁcantly advanced our understanding of MS and
permitted preclinical testing of disease therapies. Moreover, these
models have shed light on the immunological and inﬂammatory
mechanisms involved in MS pathophysiology. Indeed, most of our
current knowledge of MS has been derived from these animal
models, particularly the EAE model. Nonetheless, one must
remember that MS is highly heterogeneous in terms of its genetic
basis, environmental triggers, clinical course, pathology and
responsiveness to treatment (Friese et al., 2006). Ideally, an
effective animal model should incorporate this heterogeneity.
Although EAE must be induced by artiﬁcial immunization against
myelin, most therapies tested in MS patients are based on concepts
derived from the EAE model, which continues to be the model
system of choice.1.2.1. Experimental autoimmune encephalomyelitis
EAE is a well established model used to investigate the possible
autoimmune etiology of MS (Baxter, 2007). This model originated
with Louis Pasteur’s vaccinations with spinal cord from rabies-
infected rabbits from 1885. This acute demyelinating disorder was
later found to occur due to contamination of the inoculums by
spinal cord components (Rivers et al., 1933). Model organisms,
ranging from mice to monkeys, were immunized against myelin,
myelin components or related synthetic peptides, including
myelin oligodendrocyte glycoprotein (MOG), myelin basic protein
(MBP) and myelin proteolipid protein (PLP). The course of the
resulting autoimmune inﬂammatory demyelinating disease ran-
ged from acute monophasic to chronic progressive or relapsing-
remitting, depending on a combination of several factors including
the immunogen peptide, age, sex and the commercial source of the
animal (De Luca et al., 2010). The immune response elicited in EAE
is primarily due to the activation of myelin-reactive CD4+ Th1 cells,
leading to inﬂammatory demyelination (Zamvil and Steinmann,
1990). In all EAE models, CD4+ cells predominate in the lesions and
they are crucial for the adoptive transfer of the disease to naı¨ve
healthy animals. Nonetheless, myelin-speciﬁc CD8+ T cells also
play a role as suppressor/regulatory T cells or effector T cells in EAE
pathogenesis. Studies employing either antibody (Ab) depletion of
CD8+ T cells or genetic knockout of the CD8 gene suggest a
regulatory role of CD8+ T cells in EAE (Goverman et al., 2005). An
effector role for CD8+ T cells has also been proposed, as adoptively
transferred MBP speciﬁc CD8+ cytotoxic T lymphocytes can
mediate autoimmune disease (Huseby et al., 2001). Moreover,
MOG speciﬁc CD8+ T cells can act as effector cells in EAE and
mediate demyelination (Sun et al., 2001). While macrophages,
mast cells, eosinophils and CD8+ cells have been implicated in EAE,
the disease is considered a mainly class II CD4+ cell-mediated
process. Pathophysiological variations between speciﬁc EAE
models correlate with distinct predominating aspects of the
immune response. Various EAE models have been used to dissect
out the molecular mechanisms of the autoimmune inﬂammatory
response and to develop new therapies for MS. The main limitation
of this model is the artiﬁcial induction of a myelin-speciﬁc immune
response, which does not mimic the spontaneous disease and may
bypass key pathogenic mechanisms operating in human MS.
However, since the key target autoantigens of MS are unknown,
this is still difﬁcult to verify. Currently, it remains unclear why very
few therapies that show promise in pre-clinical EAE trials have not
shown similar efﬁcacy in MS patients. Nevertheless, EAE remains a
useful model to aid the development of novel MS treatments.
1.2.2. Viral models
Both genetic and environmental factors have been implicated in
MS, with greater importance attributed to the latter (Ascherio and
Munger, 2007a,b). Epidemiologic research has identiﬁed external
risk factors in this multi-factorial setting, and has implicated viral
and other microbial agents. Although most reports linking
infection with MS are circumstantial, efforts are ongoing to
identify speciﬁc pathogens that may be important in disease
development (Stu¨ve et al., 2004). A possible viral association with
MS is suggested by epidemiological studies (Allen and Brankin,
1993; Kurtzke, 1993; Soldan et al., 1997) and by the detection of
viral antigens (Ag) and virus-speciﬁc Abs in the majority of MS
patients. For example, Ags derived from human herpes virus type 6
have been observed in MS plaques but not in tissues from patients
with other neurological disorders (Cermelli et al., 2003; Challoner
et al., 1995; Soldan et al., 1997; Virtanen et al., 2011). Similar
ﬁndings have been reported for Epstein–Barr virus, which is in turn
implicated in MS (Jilek et al., 2008; Lucas et al., 2011; Munger et al.,
2011; Sargsyan et al., 2010; Tzartos et al., 2012). In addition, many
studies have modeled the interactions between viruses and the
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viral strains, as outlined in Table 1. The three major hypotheses
for how infections may induce immunity include: bystander
activation, epitope spreading and molecular mimicry (Fig. 1).
Bystander activation is a non speciﬁc mechanism for virus
induced autoimmunity occurring within the inﬂammatory
context generated by virus infection, especially chronic viral
infection that leads to activated lymphocytes to secrete inﬂam-
matory mediators that mediate tissue damage. Stimulation of
autoreactive T cells bearing particular Vb receptors by virus
encoded superantigens or indirectly via tissue resident APCs
activated via Toll-like receptors (TLRs) or other patterns recogni-
tion receptors (PRRs) may drive tissue injury due to cytotoxicFig. 1. Scheme of molecular mimicry and epitope spreading models of viral induced auto
APC process viral peptides and present antigen to virus epitope-speciﬁc CD4 T cells in th
barrier, releasing proinﬂammatory cytokines and chemokines (2) that activate and rec
activation allow self-antigens release (3). The CNS persistence of virus and the presence 
The similarity between some self-peptides (galactocerebroside, GALC) and viral peptide
epitope spreading model, after a persistent viral infection (1), APCs process the antigen (2
peripheral tissue, in which case the T cell would have to cross the blood–brain barrier) 
recruiting and activating monocytes and macrophages (4), which initiate the self-tissue 
activation of self-epitope-speciﬁc CD4 T cells and virus-speciﬁc CD4 T cells (7), causininﬂammatory molecules. A functional consequence of bystander
activation and local tissue damage is the epitope spreading. In the
setting of persistent infection where a prolonged anti-viral-immune
response leads to tissue destruction resulting in the release of cryptic
self-epitopes that are then engulfed and presented by APCs to T
lymphocytes leading to activated autoreactive T cells. In summary,
endogenous de novo activation of autoreactive T cells by sequestered
Ags released secondary to tissue destruction directly by virus or by
virus speciﬁc T cells is the basis for epitope spreading. Finally, the
molecular mimicry, the mechanisms most often proposed for virus
trigger autoimmunity, involves immunological cross reactivity
between self-epitopes and epitopes from a foreign pathogen
(Chastain and Miller, 2012; Fujinami et al., 1983).immunity. In black (continuous line): after an acute viral infection, macrophages or
e periphery (1a) or in the CNS (1b). Activated peripheral cells cross the blood–brain
ruit monocytes and macrophages, which cause tissue damage also by bystander
of self-antigens in the inﬂammatory context cause the self-peptides processing (4).
s (VP1) causes a cross-reaction (molecular mimicry) (5). In red (dashed line): in the
) and present it to virus epitope-speciﬁc CD4 T cells (either in the nervous tissue or in
(3). This activation causes a release of proinﬂammatory cytokines and chemokines,
destruction (5). A prolonged inﬂammation and processing self-antigens (6) induced
g an immune-mediated disease prolonged in time.
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single-stranded virus of the Picornaviridae family, which is a
natural enteric mouse pathogen that behaves as a neurotropic
virus that can replicate and persists within the CNS. Intracerebral
infection of susceptible inbred mouse strains (SLJ/J) with TMEV
leads to the induction of a late-onset demyelinating disease,
termed TMEV-induced demyelinating disease (TMEV-IDD) which
is similar in pathology to MS. TMEV is a well characterized model
used to study the potential role of pathogenic agents in the
development of MS. Several strains of TMEV exist that differ in
their neurovirulence. TMEV is subdivided into two subgroups,
GDVII and TO. The GDVII subgroup is neurovirulent and its
representative strain is the GDVII virus. The TO subgroup is less
virulent and the two representative and most commonly used
strains are the Daniels (DA) and BeAn strains that promote a
biphasic disease in which the chronic progressive phase is
associated with demyelination in the white matter of the spinal
cord (Dal Canto and Lipton, 1975). This chronic phase is considered
a model of primary progressive MS. The persistence of TMEV in the
CNS of susceptible mice is demonstrated as viral RNA and viral Ags
can be detected throughout the animal’s lifespan (Miller et al.,
1997; Oleszak et al., 2004; Rodriguez et al., 1983). In TMEV-IDD,
CNS damage is mediated by antiviral responses mediated by
pathogenic proinﬂammatory virus-speciﬁc CD4+T cells and is
characterized by immune cell inﬁltration into the CNS, causing
demyelination and disease signs. Pro-inﬂammatory cytokines
recruit monocytes and macrophages into the CNS, which cause
myelin damage. Reactivity to myelin does not appear until after the
onset of disease signs (Katz-Levy et al., 1999). Thus, the chronic
phase of TMEV-IDD is characterized by autoimmune processes due
to epitope spreading from viral determinants to self-myelin
determinants, demonstrating that viruses can trigger autoimmune
reactions. Tolerance to myelin proteins after TMEV infection
signiﬁcantly inhibits TMEV-IDD, indicating the importance of the
myelin-speciﬁc immune response in disease progression (Karpus
et al., 1995; Neville et al., 2002).
1.2.2.2. Murine hepatitis virus (MHV). Like TMEV, MHV is a natural
mouse pathogen that infects all cells types within the CNS
(Bergmann et al., 2006). Particular strains of MHV, such as John
Howard Mueller (JHM), display a distinct CNS tropism leading to
severe acute encephalitis (Bender and Weiss, 2010). Strains with a
less pronounced neurotropism, such as the gliatropic MHV-A59
strain generally establish a persistent CNS infection, leading to
chronic neuroinﬂammation and demyelination (Hosking and Lane,
2010; Knobler et al., 1981). Mice inoculated intracerebrally or
intranasally with the JHM virus or MHV-A59 strains mount a
robust immune response resulting in an inﬂux of immune cells that
largely clear the virus, although low level viral infection persists in
animals surviving the acute infection (Adami et al., 1995). In
contrast to TMEV, susceptible mice infected with MHV develop a
single major symptomatic episode (ataxia, hindlimb paresis,
paralysis), from which the majority recover. Demyelination begins
about one week post-infection, peaking at week 3–4, after which
lesion repair and remyelination may occur (Lavi et al., 1984; Jordan
et al., 1989).
Although the mechanism mediating demyelination remains
unclear, extensive evidence suggests that immune responses are
central to this process. MHV infects and replicates within
oligodendrocytes, suggesting that oligodendrocyte damage is the
main cause of demyelination (Hosking and Lane, 2010; Liu and
Zhang, 2007). However, mice exposed to immunosuppressive
doses of irradiation following JHM infection exhibit little
demyelination despite the presence of the virus in oligodendro-
cytes, and demyelination is restored when irradiated mice are
reconstituted with splenocytes from non-irradiated infected mice(Fleming et al., 1993). Similarly, T and B cell-deﬁcient RAG-1
deﬁcient mice are resistant to demyelination but exhibit demye-
lination after adoptive transfer of splenocytes from MHV-infected
mice, a process that involves the recruitment of activated
macrophages/microglia to demyelinated regions of the spinal
cord (Wu and Perlman, 1999). Most studies suggest that
macrophages are primarily responsible for the destruction of
myelin, while others have proposed that the presence of either
CD8+ or CD4+ cells is required for demyelination, but not both
subsets simultaneously (Wu et al., 2000) Both b2-microglobulin
and MHC class II-deﬁcient mice exhibit demyelination after MHV
infection. However, demyelination is less severe in CD4-deﬁcient
vs CD8-deﬁcient mice, in agreement with the observed recruit-
ment of macrophages to the CNS in these animals (Pewe et al.,
2002). There is no evidence to date of self-speciﬁc immunity in the
CNS of MHV-infected mice (Marten et al., 2001). Taken together,
ﬁndings in the MHV model suggest that demyelination in human
MS may be induced in an Ag non-speciﬁc manner if the virus is
tropic for cells of the CNS.
1.2.2.3. Semliki Forest virus (SFV). SFV is a neurotropic alphavirus of
the family Togaviridae that infects CNS neurons and oligoden-
drocytes (Fazakerley et al., 1993; Pathak and Webb, 1983). In adult
C57BL/6 and BALB/c mice the virus is largely cleared from the CNS
by 6 days post-infection (dpi). Demyelination peaks around day 14
and subsequently wanes, with sporadic and mild clinical
symptoms (Fazakerley and Webb, 1987). The demyelination
observed in SFV-infected mice appears to involve T cells, as
demyelination does not occur in nude or SCID mice (Amor et al.,
1996). Indeed, in BALB/c mice, depletion of CD8+ but not CD4+ T
cells abolishes demyelinating lesions (Subak-Sharpe et al., 1993).
Demyelination may also occur following cytolytic damage of virus-
infected oligodendrocytes (Mokhtarian et al., 2003; Pathak and
Webb, 1983). In this model in C57BL/6 mice, molecular mimicry
may also play a role in demyelination, as infected mice exhibit
proliferative T cell responses to MBP, and Abs reactive to MBP and
MOG (Smith-Norowitz et al., 2000). Indeed, it has been proposed
that the demyelinating lesions are generated mainly via Ab
responses, which are cross-reactive to MOG and the SFV E2 protein.
1.2.2.4. Sindbis Virus (SV). Infection of SJL mice with SV is another
model of demyelination that has not been extensively studied, but
that provides further proof-of-principle that pathogen infection
can lead to autoimmune disease. Infected SJL mice develop EAE-
like paralysis beginning at 6 dpi and lasting up until 8 weeks post-
infection (Mokhtarian et al., 1989). Cyclophosphamide treatment
ameliorates disease signs despite increasing the CNS viral load,
indicating that paralysis in these mice is mediated by the immune
response. CNS lymphocytes collected at 7 dpi are speciﬁc for SV but
not for MBP (Rowell and Grifﬁn, 2002). Interestingly, MBP-speciﬁc
T cell and Ab responses are detected in the periphery at 8 weeks
post-infection, suggesting that anti-myelin responses arise due to
bystander damage via epitope spreading (Metcalf and Grifﬁn,
2011). The rapid onset of symptoms following SV infection
indicates that demyelination is not the primary cause of paralysis
but may contribute to chronic disease.
To summarize this ﬁrst part of the review, viruses can induce
demyelination and autoimmunity via multiple pathways. Al-
though one of the main mechanisms of virus-induced autoimmu-
nity in many of the animal models discussed here are epitope
spreading and molecular mimicry, in other cases such as the MHV
infection the virus does not induced autoimmunity. The underly-
ing mechanisms mediating myelin destruction may differ from one
model to another and still not fully clariﬁed. Moreover, the
different clinical manifestations of each model reﬂect the broad
spectrum of symptoms experienced by patients. Of the MS models
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other models of virus-induced demyelination as it permits the
analysis of initial viral exposure and clearance, and the progression
from viral recognition by the immune system to autoimmunity.
This model has proved effective in the development of clinical
therapies for MS. Below we will review the characteristics of the
TMEV model and discuss its novel aspects with respect to
pathogenic mechanisms and the evolution of TMEV-induced brain
and spinal cord damage.
2. TMEV-IDD: models and strains
TMEV infection of mice is one of the better characterized
neurotropic viral infection models of MS. Since Max Theiler ﬁrst
isolated TMEV from the CNS of mice with spontaneous paralysis of
the hind legs (Theiler, 1937), our understanding of TMEV-IDD has
advanced greatly. In 1952, demyelination of the spinal cord of mice
infected with the Daniels (DA) strain of TMEV was described
(Daniels et al., 1952). Several years later Lipton demonstrated the
utility of TMEV infection as an experimental model of MS (Lipton,
1975).
TMEV belongs to the genus Cardiovirus of the family Piconavir-
idae and it is a positive strand RNA virus, like poliovirus, rhinovirus
or coxsackievirus. TMEV strains are divided into two subgroups,
GDVII and TO, based on the severity of the CNS disease they induce.
The GDVII subgroup (strains GDVII and FA) is highly neurovirulent
in mice and causes fatal encephalitis, resulting in death within one
to 2 weeks (Yamada et al., 1991). The TO subgroup (DA and BeAn
strains) is much less virulent and induces mono or biphasic
disease. The monophasic disease consists of transient meningoen-
cephalomyelitis, peaking one week after infection. In resistant
mouse strains the virus is cleared after approximately 3 weeks by
an intense inﬂammatory response that protects against viral
persistence and gives way to a transient stage, after which mice
generally recover without persistent neurological disease (Linds-
ley and Rodriguez, 1989; Njenga et al., 1997). However, in
susceptible mouse strains (SJL/J), TMEV induces a biphasic disease
characterized by acute encephalomyelitis followed by a chronic
inﬂammatory demyelinating disease that begins 35–45 dpi (BeAn
strain). Most of the demyelinating lesions are found in the spinal
cord, as seen in the EAE models although in EAE also occur brain
lesions (Centonze et al., 2009; MacKenzie-Graham et al., 2009;
Mandolesi et al., 2012). This phase is considered a valid model of
chronic progressive MS. TMEV persists in the CNS for the entire
lifespan of the animal and disease severity depends on the strain,
sex and age of the mouse (Kappel et al., 1990; Steiner et al., 1984),
as well as the dose and strain of the virus. TMEV persists
indeﬁnitely to varying degrees in different cell types including
monocyte/macrophages, microglia, oligodendrocytes and astro-
cytes (Clach et al., 1990; Jelachich et al., 1995, 1999). Resistance to
persistent CNS infection by TMEV is controlled by multiple genetic
loci, with the strongest linkage observed for the MHC class I H-2D
region (Brahic et al., 2005; Rodriguez et al., 1986).
Although similarities are observed, the disease induced by the
DA virus differs in several aspects to that induced by the BeAn
strain, including the cell types infected and the associated
pathology (Kang et al., 2002; Zoecklein et al., 2003). During the
acute phase of DA infection viral antigen-positive neurons are
found in the gray matter, including the cerebral cortex and
hippocampus. Some apoptotic neurons and parenchymal, peri-
vascular and subarachnoidal MNC inﬁltrates, including CD3+ T
cells, are observed (Schlitt et al., 2003). During the chronic phase of
DA infection, inﬂammation persists in the white matter of the CNS.
Demyelination with perivascular and subarachnoidal MNC inﬂam-
mation is observed in the ventral and lateral funiculi, particularly
at the ventral root exit zone of the spinal cord. During the chronicphase, viral Ag and viral genome have been demonstrated by
immunohistochemistry and in situ hybridization in oligodendro-
cytes, microglia/macrophages and astrocytes, but not in neurons
(Oleszak et al., 2004). Infectious virus and viral genome have also
been quantiﬁed in plaque assays and by reverse transcription
polymerase chain reaction (PCR), respectively. CNS cells infected
with DA virus contain 100–500 copies of viral RNA, and
quantiﬁcation of positive and negative strand RNAs in infected
CNS cells conﬁrms that RNA replication is blocked at the level of
negative-strand RNA synthesis, as postulated for other picorna-
viruses in which the main mechanism of persistence in vivo is
restriction of viral RNA replication (Cash et al., 1988). Differences
between DA and BeAn viral infection in mice may explain the
divergent disease courses previously described for these viruses
(Kang et al., 2002; Oleszak et al., 2004). In particular, the level and
avidity of virus-speciﬁc CD8+ T cells inﬁltrating the CNS could be
different after the infection with these two strains of TMEV and
may differentially inﬂuence the pathogenic and/or protective
outcome (Kang et al., 2002). Infection with DA virus results in a
greater demyelination, more viral RNA, and more antigen-positive
cells in the spinal cord as compared with the BeAn virus (Zoecklein
et al., 2003). There was a higher incidence of demyelination in the
spinal cord of mice infected with DA, but the extent of
demyelination was similar for both viral strains when compared
with mice those developed demyelination. While no differences in
brain inﬁltrating immune cells are observed between DA and
BeAn-infected mice, the latter exhibit higher titers of TMEV-
speciﬁc Ab. Functional deﬁcits measured by rotarod performance
are more severe in DA-infected mice (Zoecklein et al., 2003).
Although the capsid proteins of the BeAn and DA strains Exhibit
93% amino acid homology, the disease induced by the BeAn strain
in SJL/J mice differs from that induced by the DA strain (Tsunoda
and Fujinami, 2010); the early acute disease is attenuated in BeAn-
infected mice as opposed to the gray matter disease induced by the
DA strain of TMEV. Furthermore, although both strains induce late
chronic demyelinating disease, the kinetic of the disease induced
by each strain differs considerably. BeAn-infected SJL mice exhibit
clear disease signs at 30–45 dpi, including waddling gait and hind
leg paralysis, in function of the viral dose and the age of the
animals. By contrast, DA-infected SJL/J mice develop these signs
much later, at approximately 90–120 dpi (Njenga et al., 1999).
2.1. Pathogenesis: TMEV-IDD
2.1.1. Pathophysiology of demyelination
Intracerebral infection of susceptible mouse strains with TMEV
results in a biphasic disease of the CNS, consisting of early acute
disease and subsequent chronic demyelination. During the acute
phase, the white matter is unaffected, but multifocal inﬂammation
involving cerebral and spinal cord gray matter is observed (Lipton
and Dal Canto, 1976; Rodriguez et al., 1987b). Cellular inﬁltrates
(predominantly T cells and monocyte/macrophages) are detected
in the leptomeninges and the cerebral cortex, although inﬂamma-
tion is mainly concentrated in the subcortical gray matter, in
particular the thalamus, hippocampus and basal ganglia. In the
spinal cord, inﬂammation is restricted to the anterior horns of the
gray matter, although inﬁltration of the leptomeninges also occurs.
During the chronic phase (30–35 dpi), mononuclear cell inﬁltrates
of the spinal cord white matter consisting predominantly of T cells
and monocyte/macrophages coincide with the initiation of chronic
demyelination, and microglial activation in the white matter is
observed (Are´valo-Martı´n et al., 2003; Oleszak et al., 2004). The
demyelination process is multifocal and although it is evident
throughout the rostrocaudal length of the spinal cord, it
preferentially affects the thoracic segments (Rodriguez et al.,
1996).
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involvement of different cellular components of the immune
system. At ﬁrst, the innate immune response affects the develop-
ment of the autoimmune response (Olson and Miller, 2009). The
immune response is initiated by the presentation of persistent viral
Ags to CD4+ T cells by resident CNS Ag presenting cells (Olson et al.,
2001; Olson and Miller, 2004). Pro-inﬂammatory cytokines recruit
monocytes and macrophages into the CNS, which cause myelin
damage. The subsequent release of myelin Ags and their uptake by
APCs leads to the emergence of myelin-speciﬁc CD4+ T cells.
Reactivity to myelin does not appear until after the onset of clinical
symptoms (Katz-Levy et al., 1999). Both, CD4+ and CD8+ T cells
appear to play important roles in the pathogenesis of late chronic
demyelinating disease. Although the inﬁltrating CD4+ T cells
during the early chronic phase are speciﬁc for the virus, in the late
chronic phase CD4+ T cells can recognize host or viral Ags, as
elegantly revealed Miller et al. (1997) by demonstrating epitope
spreading to self-myelin epitopes in TMEV-IDD. CD4+ T cell
responses to the immunodominant myelin proteolipid protein
(PLP139–151) are present during late chronic phases and as the
disease progresses further, CD4+ T cell responses to multiple
myelin epitopes occur in an ordered progression (Katz-Levy et al.,
1999; McMahon et al., 2005). Therefore, autoimmune responses
against myelin are only evident during the late chronic phases of
TMEV-IDD. The possibility that a natural TMEV infection can
induce CNS autoimmunity by molecular mimicry was ﬁrst
demonstrated in elegant experiments conducted by Fujinami’s
group that showed the existence of molecular mimicry between
VP1 and lipid like structure of myelin such as galactocerebroside
(GALC) (Fujinami et al., 1988). Results from the same group also
showed that antibodies generated by immune response to TMEV
could react with myelin and oligodendrocytes contributing to
demyelination (Yamada et al., 1990). Additionally, Miller’s group
developed a model where the immunodominant myelin epitope
PLP139–151 was inserted into a nonpathogenic variant of TMEV to
produce demyelination (Olson et al., 2001). In that case, they used
engineered recombinant TMEV strains and not natural TMEV
strains and the use of different molecular constructs can be
unrealistic from the point of view of real TMEV infection and the
model of TMEV-IDD. However, they showed that a naturally
infectious virus when encoding a myelin epitope mimic can initiate
autoimmunity via molecular mimicry associated with the appear-
ance of cross-reactive Th1 cell responses to the endogenous myelin
protein. It is important to note that molecular mimicry requires the
infectious agent to encode a mimic epitope with structural and
sequential similarity to the self-peptide and must be capable of
being processed from its native protein by APCs in the infected
hosts providing the necessary accessory molecules required for
autoreactive T cell activation.
To summarize both, epitope spreading and molecular mimicry
are the main mechanisms underlying virus-induced CNS autoim-
munity (Chastain and Miller, 2012; Croxford et al., 2002; Fujinami
et al., 1983) and both mechanisms have been demonstrated in
TMEV-IDD.
The role of CD4+ T cells in the development of demyelinating
disease is supported by several lines of evidence: (i) treatment of
TMEV-infected susceptible mice with anti-IA Abs results in
decreased demyelination (Friedmann et al., 1987); (ii) CD4+-
mediated delayed hypersensitivity to TMEV Ags is associated with
myelin damage (Miller and Rodriguez, 1995); (iii) in vivo depletion
of CD4+ T cells during established disease diminishes the severity
of demyelination (Rodriguez and Lindsley, 1992); and ﬁnally, (iv)
certain CD4+ T cells generated during TMEV infection with either
the BeAn or the DA strain (Jin et al., 2009) speciﬁcally recognize
predominant viral peptides (VP1233–250, VP274–286, VP334–37).
However, it remains unclear how deﬁciencies in class II geneproducts contribute to viral persistence and the degree of
demyelination. TMEV-IDD has been reported in class II knockout
mice (Njenga et al., 1996), CD4 deﬁcient mice (Murray et al., 1998)
and nude mice (Fujinami et al., 1989; Rosenthal et al., 1986)
MHC class I-restricted CD8+ T cells have been proposed to play
effector roles in the development of demyelinating disease since (i)
CD8+ T cells inﬁltrate demyelinating lesions, (ii) in vivo adminis-
tration of CD8 antibody diminishes demyelination, and (iii) MHC
class I molecules are upregulated in the CNS in TMEV-infected mice
(rev by Drescher et al., 1997). Depletion of CD8+ T cells during
chronic phases greatly reduces myelin damage in the CNS of
TMEV-infected mice (DA strain: Rodriguez and Sriram, 1988),
while CD8-deﬁcient mice infected with the BeAn strain of TMEV
display greater susceptibility to infection and greater pathological
alterations during demyelination (Begolka et al., 1998). Interest-
ingly, autoreactive TMEV-speciﬁc CD8+ T cells have been described
by Tsunoda and Fujinami’s group (Tsunoda et al., 2002, 2005,
2006). They tested whether an autoreactive cell induced by TMEV
infection mediated cytotoxicity using a 51Cr release assay in SJL/J
mice and demonstrate that intracerebral inoculation of CD8+ T cell
clones effector cells into naı¨ve mice caused meningitis and
perivascular cufﬁng in the brain and spinal cord with no evidence
of viral antigen positive cells (Tsunoda et al., 2002, 2005).
As disease resistance partly maps to the H-2D MHC class I locus,
the CD8+ T cell response has been extensively studied. The
requirement of CD8+ cytotoxic T lymphocytes (CTL) for clearing the
virus may explain the above ﬁndings. Several years ago, the
Rodriguez group analyzed antiviral immune responses and their
modulation of TMEV-IDD (Drescher et al., 1997), and they found
that VP1 and VP2 capsid Ags of TMEV are critical in determining
resistance/susceptibility to immune-mediated demyelination.
Mice with H-2Db haplotype are resistant and resolve TMEV-
induced encephalitis following a strong CD8+ T cell response,
which clears the virus and prevents viral persistence (Lin et al.,
2002). The tentative association between the presence of
functional CD8+ T cells and resistance to TMEV-IDD has prompted
direct comparison of CD8+ T cell responses to TMEV in SJL/J and
C57BL/6 mice. Although these responses exhibit some qualitative
differences, they are quantitatively quite similar (Lyman et al.,
2004), and thus the basis for the differential virus clearance
observed in the two mouse strains remains unclear. Recent studies
using transgenic mice that express VP1, VP2 or VP2121–130 Ags have
analyzed immune responses to speciﬁc capsid Ags in the TMEV-
IDD model (DA strain: Denic et al., 2011; Pavelko et al., 2007).
Expression of speciﬁc capsid Ags is able to induce susceptibility to
demyelination in the normally resistant strain (Pavelko et al.,
2007). Moreover, susceptible transgenic mice exhibit demyelin-
ation, inﬂammation and axonal loss as compared with wild type
mice, despite suffering no apparent increase in viral load,
supporting the view that expression of viral capsid proteins
inﬂuences the extent of axonal pathology following TMEV
infection (Denic et al., 2011). On the other hand, a recent study
using the BeAn strain demonstrated that adoptive transfer of
activated CD8+ VP3159–166-speciﬁc T cell blasts shortly after TMEV
infection to boost the early antiviral response leads to clearance of
CNS virus and protection from subsequent TMEV-IDD (Getts et al.,
2010).
It was recently proposed that differential induction of
regulatory T cells (Tregs) mediates susceptibility to TMEV-IDD.
Indeed, infection of disease-susceptible SJL/J, but not resistant B6
mice leads to rapid activation and expansion of Tregs, resulting in
an unfavorable CNS ratio of Treg:T effector cells (Richards et al.,
2011). Moreover, anti-CD25-induced inactivation of Tregs in
susceptible SJL/J mice, but not in resistant B6 mice, induces a
signiﬁcant decrease in clinical disease severity concomitant with
enhanced antiviral CD4+, CD8+ and antibody-mediated antiviral
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delay in onset and progression of disease following inactivation of
Tregs in susceptible mice prior to TMEV infection would be related
to better virus clearance as a signiﬁcant decrease in viral load in the
brain was observed at day 12 post-infection. As disease progresses,
the virus spreads to the spinal cord, however, by day 28 post-
infection the viral load in anti-CD25 treated and control treated
mice is equivalent. It is important to note that inactivation of Tregs
with anti-CD25 mAb is temporary and functional Tregs return to
near frequencies within 7–10 days after the ﬁnal mAb treatment.
The fact that Treg cells proliferate preferentially in TMEV-
susceptible mice resulting in a CNS CD8+ T effector:Treg (1:4 at
day 7 post-infection) less favorable for virus clearance than the
ratio (1:1.2 at day 7 post-infection) in resistant mice during the
acute TMEV infection may control the efﬁciency of the antiviral-
immune response resulting in virus persistence. This is the ﬁrst
report demonstrating that TMEV-induced Treg activation differ-
entially regulates susceptibility to immune-mediated disease in
different mouse strains and provides new mechanistic insights into
infection-induced autoimmunity.
In addition to their role in TMEV persistence, the action of
macrophages/microglia as effectors of demyelination is well
documented (Oleszak et al., 2004). Several lines of evidence
suggest that macrophages (Pena-Rossi et al., 1997), and to a lesser
extent glial cells, serve as the site of TMEV persistence (Clach et al.,
1990; Dal Canto and Lipton, 1982; O’Shea et al., 1997; Zheng et al.,
2001). Active viral replication in macrophages is indicated by the
immunohistochemical detection of virus accompanied by cyto-
skeletal changes in macrophages (Dal Canto and Lipton, 1982), the
presence of a large TMEV Ag burden and the detection of the viral
genome within macrophages (Lipton et al., 1995). Resident CNS
cells such as astrocytes and microglia are important reservoirs of
TMEV (Zheng et al., 2001). Within the CNS, APCs like microglial
cells (Mack et al., 2003; Olson and Miller, 2004) act as a ﬁrst-line of
defense against TMEV infection and inﬂammation, but in the
chronic phase they may help sustain the self-destructive
environment by secreting inﬂammatory factors and/or presenting
Ag to T cells. Furthermore, dendritic cells, though not CNS-resident
cells, have emerged as key APCs, even within CNS (Chastain et al.,
2011). Astrocytes are the most abundant cell type in the brain and
they are not commonly associated with immunological responses
but rather, they play a regulatory role in TMEV-IDD (Carpentier
et al., 2008). Inﬂammation, involving the inﬁltration of blood-
derived cells, particularly T and B lymphocytes and monocytes,
together with the activation of resident microglia and astrocytes, is
the earliest pathologic event in the spinal cord of infected mice,
slightly preceding demyelination. Monocyte-derived macrophages
and activated microglia account for over half of the inﬂammatory
cells in spinal cords, as evaluated by FACS of isolated inﬂammatory
cells (Olson et al., 2001). The onset of demyelination in the spinal
cord coincides with the inﬂammatory response, which co-localize
in areas of viral expression, as evident by in situ hybridization and
immunohistochemistry for TMEV. Demyelinated lesions are
concentrated in the thoracic and cervical spinal cord areas, and
while the ventral and lateral funiculi are consistently lesioned, the
dorsal funiculus is more variably affected (Ure and Rodriguez,
2002).
As mentioned above, myelin degeneration in TMEV-IDD is
probably mediated by a range of processes, including direct
phagocytosis of myelin. Cytotoxic factors are also likely to be
involved, including proteases, cytokines, complement, nitric oxide
(NO) metabolites and reactive oxygen species, generated in part by
macrophages/microglia of the myelin sheath, sparing oligoden-
drocyte cell bodies (Langrish et al., 2005; Liuzzi et al., 1995;
Oleszak et al., 2004). Alternatively, demyelination may be
occurring secondary to a primary insult to the oligodendrocytecell body. Oligodendrocytes exhibit a degenerative pathology in
lesions, including swelling and vacuolation, and decreased myelin
protein immunoreactivity provides an index of myelin disruption
(Rodriguez, 1985). In addition, some demyelination is associated
with Wallerian degeneration, as axonal loss is observed in
chronically diseased mice, although this issue remains controver-
sial. Finally, excitotoxicity has emerged as another possible
mechanism underlying demyelination and axonal damage in the
TMEV model. We demonstrated the beneﬁcial effect of adminis-
tration of NBQX, a classical AMPA/kainate receptor antagonist, in
TMEV diseased mice, probably due to the blockade of excessive
glutamate release (Docagne et al., 2007). These results are
consistent with previous ﬁndings in the acute EAE model (Pitt
et al., 2000), the chronic relapsing EAE model (Smith et al., 2000)
and in MS patients (Srinivasan et al., 2005). In this scenario,
oligodendrocyte death and myelin disruption may also occur due
to TMEV-induced cytolysis or apoptosis. Cyclooxygenase-2 (COX-
2) is expressed in dying oligodendrocytes at the onset of
demyelination in TMEV-IDD (Carlson et al., 2006), increasing their
susceptibility to excitotoxic death (Carlson et al., 2010). TMEV
infects oligodendrocytes both in vivo (during the chronic phase)
and in vitro, as the DA strain of TMEV kills oligodendrocytes in
culture (direct lytic infection). Several studies have also demon-
strated infection of oligodendrocytes by the DA strain in vivo,
which is localized in degenerating cells (Ghadge et al., 2011). Nude
mice with a limited T cell response develop demyelinating lesions
following TMEV infection, although the overall extent of demye-
lination is limited (Roos and Wollmann, 1984). Oligodendroglial
apoptosis has also been described during the chronic phase of
TMEV infection, as revealed by double staining of TUNEL-positive
nuclei with oligodendrocyte and macrophage/microglia markers
(Rose et al., 1998; Tsunoda et al., 1997). While the pathogenic
mechanisms associated with TMEV-IDD appear to be more
complex than previously thought, most studies suggest that the
immune system plays a prominent role in demyelination, although
a wide variety of cells and molecules regulate demyelination and
axonal damage in the TMEV model (Fig. 2).
2.1.2. Pathophysiology of neurodegeneration: axonal damage
Neurodegeneration, axonal and/or neuronal damage has been
recognized as a component of MS since the pioneering studies of
Charcot (1868). However, MS, EAE and most TMEV studies have
typically focused on demyelination, and axonal injury has only
recently attracted the attention of researchers. Pathological studies
have highlighted the existence of axonal injury in MS patients
(Ferguson et al., 1997; Trapp et al., 1998; Trapp and Nave, 2008),
although, the temporal proﬁle of demyelination and axonal loss in
MS patients, and their respective contribution to the clinical and
electrophysiological abnormalities, are not completely under-
stood. In the TMEV model of progressive MS, demyelination in the
spinal cord is followed by the loss of medium-to-large myelinated
axons, it is associated with electrophysiological abnormalities and
is strongly correlated with spinal cord atrophy and reduced motor
coordination (McGavern et al., 2000).
Axonal injury in TMEV-IDD was ﬁrst described during the
chronic phase of the disease (DA strain) by Dal Canto and Lipton
(1975). It was believed that axonal damage occurred secondary to
severe inﬂammatory demyelination, whereby the myelin and/or
oligodendrocytes are injured ﬁrst, and the lesions subsequently
extend from the myelin (outside) to the axon (inside). In the last 20
years, interest in axonal damage as the potential cause of the
irreversible neurological deﬁcits in MS has led to further analyses
of TMEV-induced axonal degeneration. This research is focused
along two main lines: that led by the group of Tsunoda who
proposes that early axonal damage occurs prior to demyelination
(Tsunoda and Fujinami, 2002), while the Rodriguez group
Fig. 2. Pathogenic mechanisms involved in demyelination in the TMEV-IDD model. Cells of the immune system potentially involved in demyelination. APCs can take up
antigens from TMEV or from self-tissue (myelin or oligodendrocyte proteins). Antigens are processed and presented to T cells via the TCR in the context of MHC class I or class
II. Activated cytolytic T cells (MHC class I) induce damage by direct lysis of the target. Th cells (activated by MHC class II) release inﬂammatory cytokines that also activate
monocytes/macrophages and microglial cells. B cells recognize surface antigen and when facilitated by T cells (Th2), secrete antibodies speciﬁc for foreign and self-epitopes.
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demyelination in the CNS and that the severity of axonal loss is
closely correlated with the degree of spinal cord atrophy and
neurological deﬁcits (McGavern et al., 2000). Tsunoda and
Fujinami labeled non-phosphorylated ﬁlaments to reveal damaged
axons in the white matter of the spinal cord one week after TMEV
infection (DA strain: Tsunoda and Fujinami, 2010). This axonal
damage was independent of T cell inﬁltration and the presence of
virus-infected cells. At this time point (7 dpi), T cells and virus-
infected cells are present in the gray matter of the brain. During the
presymptomatic phase (2–3 weeks post-infection) axonal damage
in the spinal cord white matter is associated with activation of
microglia and macrophages, while there is little inﬂammation and
no viral Ags are detected. Because the magnitude of demyelination
increases at 4–5 weeks post-infection, axonal degeneration was
proposed to precede demyelination in the TMEV model (Tsunoda
et al., 2003). Based on the above ﬁndings and other more recent
observations (Tsunoda et al., 2007a), an inside-out lesion model of
TMEV infection was proposed as a self-defense mechanism against
viral spreading (Sato et al., 2011). In this scenario, the lesion
develops in the axon (inside) and extends to the myelin (outside),
and thus, axonal damage represents the primary event that is
followed by secondary demyelination (Fig. 3).
During the chronic phase of TMEV infection with the DA strain,
Rodriguez and co-workers described, in a detailed and elaborated
study, spinal cord atrophy in the ventral and lateral funiculi but not
in the dorsal area, with a signiﬁcant decrease in the number of
medium-to-large myelinated axons at 195–220 dpi (McGavern
et al., 1999, 2000). As spinal cord atrophy was not observed in
resistant C57BL/10 mice, the authors suggested that spinal cord
atrophy occurs as a consequence of demyelination during the
chronic phase, and that it is unrelated to neuronal infection duringthe acute phase, which occurs in both resistant and susceptible
mice. However, the signiﬁcant decrease observed in medium-to-
large myelinated axons in normally myelinated areas during the
chronic phase of TMEV infection (Sathornsumetee et al., 2000)
suggests that axonal degeneration may be independent of
demyelination in at least some CNS areas during the late chronic
phase. There is no consensus about the timing and the precise
mechanism of axonal damage in the TMEV-IDD model of MS.
Nevertheless, the observed axonal and functional preservation in
chronically demyelinated mice genetically deﬁcient in perforin
(Howe et al., 2006), and the preservation of motor function (Rivera-
Quinones et al., 1998) and axon integrity (Ure and Rodriguez, 2002)
seen following genetic disruption of MHC class I function during
chronic demyelination, strongly support the immune-mediated
injury model. In MS lesions, CD8+ T cells are the most abundant
lymphocytes (Babbe et al., 2000) and their presence is correlated
with axonal injury (Bitsch et al., 2000). CD8+ T cells directed against
a TMEV viral peptide, VP2121–130, contribute to the loss of motor
function by disrupting axonal transport in IFN-gR/ mice, a viral
model of rapid demyelination (Howe et al., 2007). However,
despite the signiﬁcant advances in our understanding of TMEV
pathogenesis in recent years, the precise mechanisms underlying
axonal neurodegeneration in TMEV infection remain unclear in
terms of timing of occurrence, or if it is the cause or the
consequence of demyelination. Demyelination may be necessary
but not sufﬁcient condition for motor deﬁcits associated to TMEV
infection. The idea most consolidated is that demyelination creates
a permissive environment wherein the naked axon becomes
susceptible to immune-mediated injury.
Although axonal degeneration is considered the end result in
most neuropathologies, experimental and clinical ﬁndings dem-
onstrate that axonal degeneration can itself trigger secondary
Fig. 3. Models proposed to explain the axonal degeneration and demyelination in the TMEV model. In the Outside-In model, the lesion develops from the outside (myelin) and
extends inwards (to the axon). Myelin and/or oligodendrocytes represent the primary targets for injury and after the primary destruction of myelin axonal damage is a
secondary consequence. In the Inside-Out model, lesions extend from the axon to myelin. The primary target in this scenario is the axon or its cell body, the neuron, and the
primary axon injury drives secondary demyelination.
Adapted from Tsunoda and Fujinami (2002).
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axonal degeneration induced by spinal cord injury at sections
distal to the transection site (Wallerian degeneration), oligoden-
drocyte apoptosis is observed along the degenerating ﬁber tracts
and it even extends into regions at a distance from the lesion
(Tsunoda et al., 2007a). Multiple mechanisms have been implicat-
ed in oligodendrocyte apoptosis, including microglial activation
with the release of cytotoxic mediators, glutamate mediated
excitotoxicity and the disruption of cross-talk between axons and
oligodendrocytes (Jack et al., 2007; Li et al., 2005; Matute et al.,
2001).
According to the inside-out model, TMEV ﬁrst infects neurons in
the gray matter of the CNS, damaging their axons, which in turn
leads to the degeneration of the distal stumps of the axons of the
spinal cord as early as one week after DA infection. In the spinal
cord, axon degeneration and/or apoptotic oligodendrocytes may
activate local microglia and macrophages, which can induce
demyelination through the secretion of inﬂammatory cytokines,
chemokines and proinﬂammatory mediators. Activated microglia
and macrophages phagocytose degenerated oligodendrocytes,
myelin and axons, resulting in persistent viral infection and tissue
damage. Infected degenerated oligodendrocytes phagocytosed by
macrophages/microglia may contribute to persistence of immune
viral responses by presenting viral antigens or myelin epitopes to T
cells. However, several important questions remain unanswered in
this model, including: what are the neuronal populations and
speciﬁc brain structures that contribute to such rapid axonal
degeneration in the spinal cord. Like the murine neurotropic virus,
TMEV uses axonal transport to spread through the CNS. As such,
the axonal degeneration observed in the host may represent a
protective response to prevent TMEV from spreading, further
blocking disease expansion (Tsunoda et al., 2007b; Tsunoda, 2008).
However, no deﬁnitive data have demonstrated that this speciﬁc
sequence of events occurs. Chronic spinal cord pathology and
axonal injury may occur as a result of virus-induced autoimmunity
(Miller et al., 1997), or due to bystander damage by microglia/
macrophages or T cells present in the immune repertoire
(Rodriguez et al., 1996). It should be noted that demyelination
predisposes bare axons to subsequent injury by cytokines,
inﬂammatory cells and nitric oxide, thus creating a microenviron-
ment conducive to possible irreversible deﬁcits. Not all axonal
degeneration in MS can be explained by the two models proposedabove. It is likely that both scenarios exist at different stages and
contribute to the development of an immunopathological cycle
leading to continuous disease progression (Fig. 3).
An important aspect not considered in the aforementioned
studies is the temporal pattern of brain pathology following TMEV
infection in susceptible SJL/J mice. In the classical TMEV model, the
disease induced by the less virulent viral strains (DA and BeAn) is
characterized by transient meningoencephalomyelitis, which
peaks about 7 dpi and clears from the brain after approximately
3 weeks. This gives way to a chronic demyelinating stage with
progressive neurological deﬁcits in which most of demyelinating
lesions affect the spinal cord (Dal Canto et al., 1996). Accordingly,
we will focus our discussion on the expression of speciﬁc markers
for microglia (Iba-1; Wako Pure Chemical Industries, Ltd., Osaka,
Japan), axonal density (pan neuroﬁlament; Enzo Life Sciences UK
Ltd., UK) and the myelin protein CNPase (myelin 20,30-cyclic
nucleotide 30-phosphodiesterase; Sternberger Monoclonals Incor-
porated, MD, USA) at various time points following TMEV infection
with the DA strain in two brain structures, the motor cortex and
brainstem.
The expression proﬁle of microglia staining in the motor cortex
of TMEV-infected mice reveals that as expected, the highest levels
of activation occur in the acute phase (Oleszak et al., 2004) due to
the injection of virus. However, in the chronic stages (180 dpi),
microglia activation is greater than in sham animals (Fig. 4),
accompanied by a decrease in axonal density (staining with pan
neuroﬁlament) and reduced expression of CNPase (Fig. 5).
Therefore, in the chronic phases of TMEV infection might be
occurring cortical demyelination and activation of microglia, as
described in MS patients, but it is necessary to perform additional
histological analysis with Luxol fast blue and electronic microsco-
py to reinforce the possibility of cortical demyelination presence in
the TMEV model. In the brainstem, two waves of microglial
activation occur in the acute and chronic phases (180 dpi),
indicating that inﬂammation persists throughout the disease
course (Fig. 6). Moreover, we observed decreased axonal density in
the brainstem and loss of CNPase immunoreactivity in the early
preclinical phase (35 dpi) and in the late phase (180 dpi),
indicating that brain pathology persists after the acute phase of
the disease (Fig. 7). These ﬁndings indicate that in the classic SJL/J
mouse model of demyelination, brain pathology occurs in speciﬁc
brain areas, including the cortex and brainstem, demonstrating
Fig. 4. Microglial activation in the motor cortex of TMEV-infected susceptible SJL/J mice. (A) Representative sections (frozen sections obtained by criostate) of the motor cortex
showing microglia staining by Iba-1 in sham mice and in the acute (19 dpi), early preclinical (35 dpi) and chronic phases (180 dpi) of TMEV-IDD. Scale bars 100 mm. (B)
Scheme showing the time course of Iba-1 expression throughout the disease course in susceptible SJL/J infected mice.
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within 3 weeks, as previously proposed (Oleszak et al., 2004). Our
ﬁndings also suggest that disease signs observed during the
chronic phase of the disease may be not exclusively due to the
spinal cord pathology.
As expected, we observed that TMEV-infected mice exhibit
spinal cord inﬂammation, demyelination, axonal loss and motor
deﬁcits in the chronic stages (Are´valo-Martı´n et al., 2003; Lorı´a
et al., 2010; Ortega-Gutie´rrez et al., 2005). Pathological alterations
in the brain, including those affecting the gray matter structures,
have recently been described in the EAE model (immunization
with MOG35–55), mainly in the cortex, striatum and cerebellum
(Centonze et al., 2009; MacKenzie-Graham et al., 2009; Mandolesi
et al., 2012). However, few studies of the expression of markers of
inﬂammation and neurodegeneration in the brain of TMEV-
infected mice have demonstrated a dynamically regulated
temporal expression pattern after viral infection. In an analysis
of the expression of the protease Kallikrein 6 in the TMEV-IDD
model, brain pathology was described at early (40 dpi) but not lateFig. 5. Axonal density and myelin expression in the motor cortex of TMEV-infected suscep
the motor cortex showing axonal density (pan neuroﬁlament: pan NF staining) and CNPa
the chronic phase (180 dpi). (B) Scheme showing the time course of pan NF and CNPachronic stages (180 dpi: Scarisbrick et al., 2012), in contrast to our
ﬁndings. Using a grading scale of 0–4 to quantify the pathological
parameters (Denic et al., 2011; Pavelko et al., 2007), the higher
magnitude of brain pathology observed in our study is likely to be
due to the higher viral dose used: 2  106 plaque-forming unit
(pfu) (brain pathology at 180 dpi) vs 2  105 pfu (no brain
pathology at 180 dpi). Interestingly, another study in the TMEV
model reported CD45+ cell activation, a marker of inﬂammation, in
the forebrain, which was mainly observed in the subventricular
zone, but also in the anterior cortex, hippocampus, brainstem and
other brain areas during the preclinical, early onset and chronic
phases of the disease (Goings et al., 2008). However, the highest
levels of activation were observed in the cervical spinal cord during
the chronic phase. These observations raise novel questions about
the existence of pathological changes exclusively in the spinal cord
during chronic phases of the disease, and suggest that alterations
in brain structures may also contribute to the neurological deﬁcits
that have been classically associated with spinal cord demyelin-
ation/neurodegeneration. In fact, recent neuroimaging studiestible SJL/J mice. (A) Representative sections (frozen sections obtained by criostate) of
se expression (Scale bars: 200 mm) in sham animals and TMEV-infected mice during
se expression throughout the disease course in susceptible SJL/J infected mice.
Fig. 6. Microglial activation in the brainstem of TMEV-infected susceptible SJL/J mice. (A) Representative brainstem sections (frozen sections obtained by criostate) showing
microglia stained with Iba-1 in sham mice and in the acute (19 dpi), early preclinical (35 dpi) and chronic phases (180 dpi) in TMEV-IDD mice. Scale bars: 100 mm. (B) Scheme
showing the time course of Iba-1 expression throughout the disease course in susceptible SJL/J infected mice.
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notably the thalamus, showing a strong correlation with disability
(Pirko et al., 2009). Additional volumetric MRI studies demonstrate
that signiﬁcant brain atrophy accompanies the development of the
progressive TMEV-induced disease. In that case also brain atrophy
correlates with disability assessed by rotarod assay (Pirko et al.,
2011). Other studies related to TMEV infection in other strain of
mice such as the C57/BL6 strain showed severe hippocampal
degeneration and spontaneous seizures at 2 months post-infection
indicating that viral infection of the CNS can lead to long-term
neurologic defects, including increased risk for the development of
epilepsy (Stewart et al., 2010).
2.2. Remyelination in TMEV-IDD
Various theories have been advanced to explain the oligoden-
drocyte damage observed in MS lesions. The prevailing, albeit
circumstantial, view is that this damage is incurred via a variety
of immunological mechanisms, involving anti-MOG Abs, theFig. 7. Axon density and myelin expression in the brainstem of TMEV-infected susceptible
showing axon density (pan neuroﬁlament: pan NF staining) and CNPase expression (Scale
(180 dpi). (B) Scheme showing the time course of Pan NF and CNPase expression throuproduction of proinﬂammatory cytokines by monocytes/macro-
phages and lymphocytes, T-cell-mediated injury (via CD8+ MHC
class I-restricted cytotoxicity), immunoglobulins and activated
complement components, apoptosis and other oligodendroglio-
toxic factors (Dhib-Jalbut, 2007).
An important question is whether myelin repair can restore
neurological function following a progressive CNS demyelinating
disease that induces axonal damage. In human MS, remyelination
can occur after demyelination (Hirano, 1989) and may contribute
to the recovery observed after exacerbation (McDonald, 1974). In
early MS lesions, myelin repair mediated by oligodendrocytes
(Bru¨ck et al., 1994) and Schwann cells can occur. Indeed, in patients
with recent onset of MS, oligodendrocytes are found at high
densities in lesions (Bru¨ck et al., 1994; Raine et al., 1981), while the
number of oligodendrocytes is decreased and limited remyelina-
tion occurs in the lesions of patients who have had MS for many
years (Ozawa et al., 1994). Remyelination frequently occurs
following recruitment and repopulation of the plaque by
oligodendrocytes, and migration of oligodendrocyte precursor mice. (A) Representative brain stem sections (frozen sections obtained by criostate)
 bar: 200 mm) in sham animals and in TMEV-infected mice during the chronic phase
ghout the disease course in susceptible SJL/J infected mice.
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(Blakemore, 2008; Nait-Oumesmar et al., 2007). As a rule, new
lesions undergo remyelination to varying degrees, which is either
interrupted or confounded by recurrent activity. Depletion of
oligodendrocytes or their progenitors may be one explanation for
the lack of myelin repair observed following chronic CNS
demyelination (Franklin, 2002). Thus, enhancing remyelination is
an important therapeutic strategy for MS that requires further study.
Although remyelination can occur in the TMEV-IDD model, it is
generally incomplete. Lesions from chronically infected suscepti-
ble mice reveal minimal spontaneous myelin repair (Bieber et al.,
2005; Dal Canto and Lipton, 1975; Rodriguez and Lennon, 1990),
despite an increase in the number of progenitor cells (Prayoonwi-
wat and Rodriguez, 1993). Dysregulation of oligodendroglial
progenitor cell differentiation may account for the lack of
regeneration in this MS model (Ulrich et al., 2008). As observed
in MS, there is clear ultrastructural evidence of attempted but
generally abortive remyelination in TMEV-IDD, and different
approaches have indicated that immune responses may underlie
the lack of remyelination. Pioneering work described that
remyelination in mice infected with the DA strain appears late
and is incomplete (Dal Canto and Lipton, 1975), however,
inoculation of the cell adapted WW strain of TMEV to outbred
CD1 mice develop a remitting relapsing course characterized by
extensive remyelination during the periods of remission (Dal
Canto and Barbano, 1984; Dal Canto and Lipton, 1980). In that case
authors show that Schwann cells, in association with a lack of
gliosis, were the predominant myelinating cells in the outer white
matter, but oligodendrocytes were numerous and very active in
the inner portions of the spinal cord column being able to complete
remyelination. It seems that the host inﬂammatory response to DA
virus strain is responsible for myelin injury subsides, impeding
remyelination, in this TMEV model (Dal Canto and Lipton, 1980).
Classical studies using immunosuppressive drugs such as cyclo-
phosphamide demonstrated that myelin repair is enhanced
(Rodriguez and Lindsley, 1992), suggesting that myelin repair
may be a natural phenomenon that is suppressed by a chronic
inﬂammatory response to Ags present in the CNS.
There are currently no therapeutic strategies available to
promote remyelination and enhance repair mechanisms in MS.
However, experimental data in the TMEV-IDD model gave rise to the
hypothesis that immunoglobulins may promote remyelination.
Thus, immunoglobulins directed against spinal cord homogenates
and intravenously administered polyclonal immunoglobulins (IVIg)
facilitate remyelination in the TMEV model (Rodriguez et al., 1987a;
Rodriguez and Lennon, 1990). There is no doubt about the
immunomodulatory and anti-inﬂammatory properties of IVIgs that
might be the basis for their capacity to promote remyelination in
TMEV-IDD. Although IVIgs do not inﬂuence the function of
oligodendroglial cells in vitro (Warrington et al., 2000) could protect
oligodendrocytes against complement-mediated injury and thus
provide more cells that could engage in remyelination. In addition,
IVIgs could modulate microglial function, may be creating a
microenvironment permissive for remyelination. In additional
studies by Dr. Rodriguez’s group, monoclonal antibodies (mAbs)
generated against spinal cord antigens were generated and tested in
TMEV-infected mice. The ﬁrst remyelinating-promoting mAb
identiﬁed was SCH 94.03 (Miller et al., 1994). In the process of
characterizing this IgM, they found that it bound to glycolipids on
the surface of live oligodendrocytes. A second mouse IgMkappa
monoclonal antibody (mAb) (SCH79.08) raised against normal
mouse spinal cord homogenate, reacts with myelin basic protein and
also promotes remyelination. Because these two mAbs recognize
different oligodendrocyte antigens, several previously identiﬁed
oligodendrocyte-reactive IgMkappa mAbs (O1, O4, A2B5, and HNK-
1), each with distinct antigen speciﬁcities, were evaluated and foundto promote remyelination (Asakura et al., 1995, 1998). Interestingly,
these mAbs had relatively conserved germline sequences suggesting
that the mechanism of action of IgMs to facilitate remyelination
requires recognition of oligodendrocyte plasma membrane lipids.
The shared characteristics of these mAbs are an IgM isotype and the
capacity to bind oligodendrocytes. The following step was the
identiﬁcation of human antibodies that promote remyelination on
the basis that natural antibodies present in human population
bound oligodendrocytes (Rodriguez et al., 2009; Warrington et al.,
2000). Two humans IgMs (sHIgM22 and sHIgM46) promoted
signiﬁcant remyelination in TMEV-infected mice. These human
monoclonal Abs that bind to the surface of rat and human
oligodendrocytes were shown to exhibit remyelinating properties
not only in the TMEV model but also in lysolecithine-induced
demyelination model (Bieber et al., 2002; Warrington et al., 2004,
2007). When testing IVIG and polyclonal human IgM for the ability to
promote remyelination in the TMEV model, it was clear that
polyclonal IgMs and the two human monoclonal IgMs were superior.
IVIG may be effective in the TMEV model by modulating the immune
response, whereas the IgMs may act directly on the cells of the
nervous system (Warrington et al., 2000). It is proposed that the
mechanism of action of IgMs is through lipid microdomain signaling
by transient calcium inﬂux in glial cells (Solda´n et al., 2003), however
although it is clear that IgM-mediated repair required binding to
speciﬁc antigens on the oligodendrocyte membrane, initiating a
signal that may result in oligodendrocyte proliferation and/or
protection, the exact mechanism of action is not fully understood.
Importantly, these studies suggest that oligodendrocyte-reactive
natural autoantibodies may provide a powerful therapeutic way to
induce remyelination in multiple sclerosis patients.
Clinical trials with IVIg have so far failed to demonstrate clinical
improvement in MS patients, although these studies only
employed IgGs preparations. However, recent experimental data
from in vivo and in vitro studies underline the importance of IgM for
remyelination (Trebst and Stangel, 2006; Wright et al., 2009).
Further clinical trials will therefore be required to evaluate the
remyelination potential of IgM in human disease. The design of
monoclonal Abs capable of promoting remyelination provides a
basis for the development of new speciﬁc therapies derived from
biological products such as polyclonal immunoglobulins (War-
rington and Rodriguez, 2010).
3. The TMEV model: a preclinical model of MS
No effective cure has yet been designed for MS, although several
genetic and environmental risk factors have been identiﬁed and
treatments are now available that effectively modify the disease
course. However, to elucidate the mechanism of disease onset and
progression, and to evaluate therapeutic and reparative
approaches, new animal models of MS are needed. As MS is a
complex disease of unknown etiology a single animal model is
unlikely to represent all pathological and clinical features. In
addition to EAE, TMEV-IDD represents a valid autoimmune model
of primary progressive MS with viral etiology that has been used
for preclinical drug-screening (Denic et al., 2010). Indeed, it is an
ideal model to screen drugs designed to promote remyelination
and protect axons.
3.1. Therapies developed in the TMEV-IDD
The ultimate aim of research using animal models of human
disease is to understand the pathogenesis of the disease and
translate these ﬁndings into rational therapeutic approaches. The
two main animal models of MS, EAE and TMEV-IDD, have
improved our understanding of this disease and facilitated the
development of clinical therapies. While both models exhibit
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stressed that MS is a uniquely human disease. The analysis of
therapeutic success or failure may aid the development of more
directed, effective treatments for MS, with fewer adverse effects.
Despite extensive screening for new targets in EAE and TMEV-IDD
models, only a few of the established MS therapies have been
developed in animal models. Successful therapies developed in the
EAE model include glatiramer acetate (ﬁrst line therapy),
mitoxantrone and natalizumab (second line therapies: Kieseier
and Hartung, 2003; Steinman and Zamvil, 2005). In the TMEV
model anti-adhesion molecule therapy was efﬁcacious too (Inoue
et al., 1997). One of the most successful therapies for MS is
interferon (IFN) b, a treatment classically linked to viral infection
and resistance (Paty and Li, 1993). Analysis of IFN-b treatment in
the TMEV model demonstrated its modulation of MHC class I
expression in the brain (critical for CD8+ T cells) and identiﬁed its
short and long-term effects (Njenga et al., 2000). Intravenous
administration of polyclonal human immunoglobulins exerts
reparative effects in the TMEV model (Warrington et al., 2007).
Natural auto-Abs were recently developed that bind to oligoden-
drocytes and stimulate these cells to produce new myelin
(Warrington and Rodriguez, 2010). However, it takes many years
to translate an effective therapeutic treatment from the bench to
the bedside, and despite the differences between humans and
animals, it is unlikely that any progress in the treatment of MS will
be possible without the knowledge obtained from animal research.
We compare (Table 2) the outcome of MS related clinical trials to
outcome in the TMEV model showing that TMEV-IDD may be an
accurate predictor of response to therapies.
3.2. Unsuccessful MS therapies
Unfortunately, many agents that effectively modify disease
activity in the animal models have no therapeutic effects or
produce adverse effects in MS patients. These discrepancies led to
the publication of several papers suggesting that the animal
models used, particularly the EAE model, are not accurate models
of MS (Sriram and Steiner, 2005; Steinman and Zamvil, 2005).
There may be several explanations for these divergent ﬁndings,
including genetic (species differences, characteristics of inbred
animals), pathogenetic (individual variations between MS
patients), environmental and even kinetic differences (different
ontogeny and biorhythms, temporal differences in immune
reactivity and response to therapies) between animal models
and humans. Nonetheless, important aspects of the etiopathogen-
esis of MS, including susceptibility genes, mechanisms of immuneTable 2
Comparison of treatment efﬁcacies in Theiler’s murine encephalomyelitis virus and mu
Treatment Treatment effect in TMEV Reference 
IFN-b Effective Njenga et al. (2000) 
IFN-g Effective Rodriguez et al. (2003) 
Glatiramer acetate Effective Ure and Rodriguez (2002) 
Linomide Ineffective Drescher et al. (1998) 
Anti-TNF a Exacerbated Paya et al. (1990) 
Intravenous
immunoglobulin
Effective Rodriguez and Lennon (1990) 
Anti-CD4 Effective Welsh et al. (1987) 
Anti-CD8 Effective Rodriguez and Sriram (1988) 
Cyclophosphamide Effective Lipton and Dal Canto (1976) an
Rodriguez and Lindsley (1992)
Cyclosporine Moderately effective Rodriguez and Quddus (1986) 
Anti-VLA4 Effective Inoue et al. (1997) 
Cannabinoid
derivatives
Effective Croxford and Miller (2003) and
Are´valo-Martı´n et al. (2003)cell activation, immunoregulatory circuits, and mechanisms of
axonal damage and repair have been elucidated by studying
animal models. Moreover, several emerging MS therapies are
currently in the preclinical testing phase in EAE or TMEV-IDD
models (Weber et al., 2007). However, further improvements in the
animal models used to study MS are required so that they may
better reﬂect the pathogenesis and heterogeneity of this disease
(Baker and Amor, 2011; Moreno et al., 2012).
4. Revising concepts and perspectives
In the last decade, the concept that TMEV-IDD constitutes a
chronic progressive inﬂammatory disease of the CNS, with spinal
cord demyelinating lesions and secondary neurodegeneration, has
been challenged by evidence suggesting that axonal damage may
occur independently of demyelination. In addition to the more
commonly described white matter demyelination and axonal
atrophy in the spinal cord, lesions can also affect the gray matter,
both in the acute polioencephalomyelitic phase (acute phase) and
the late chronic phase, in which brain pathology is detected in
areas including the motor cortex and brainstem.
Several ﬁndings have enhanced the interest in the role of CD8+ T
cells in MS. In TMEV-IDD, CD8+ T cells play dual roles. Resistant
strains of mice mount a strong CD8+ T cell response to eliminate
the virus from the brain and prevent spinal cord pathologies
(Mendez-Fernandez et al., 2003). In susceptible strains, CD8+ T
cells help to clear the virus from the CNS during the acute phase of
TMEV-induced disease, thereby fulﬁlling a partially protective role.
However, during the chronic phase, both CD4+ and CD8+ T cells
exert harmful effects (Deb et al., 2009, 2010). Recent studies
support the view that CD8+ T cells injure denuded axons after
recognizing axonal MHC class I. Accordingly, deletion of b-2
microglobulin ameliorates spinal cord lesion load in one of two
susceptible mouse strains, preserving axons and motor function,
and promoting recovery of brainstem N-acetylaspartate (NAA)
levels. These ﬁndings point to CD8+ T cells as the primary mediator
of axonal injury in the TMEV model (Denic et al., 2012) and suggest
that these cells may induce long term injury in MS.
Natural regulatory T cells (nTregs – CD4+CD25+Foxp3+)
generated in the thymus can limit the activation, trafﬁcking,
and effector functions of CD4+ and CD8+ T cells. Recently, several
TMEV-IDD studies have investigated whether these cells can
mediate genetic susceptibility to TMEV-induced autoimmune
disease, resulting in increased activation of Tregs in susceptible
mice, which may dampen the virus-speciﬁc CTL response.
Inactivation of Tregs prior to infection of susceptible mice resultsltiple sclerosis.
Treatment effect in MS Reference
Effective IFNb MS Study Group, Neurology 1993
Paty and Li (1993)
Exacerbated Panitch et al. (1987)
Effective Johnson et al. (1995)
Toxic Noseworthy et al. (2000)
Exacerbated Lenercept MS Study Group, Neurology 1999
Effective Fazekas et al. (1997)
Ineffective Van Oasten et al. (1997)
Untested –
d Moderately effective Weiner et al. (1993)
Moderately effective Cyclosporine MS Study Group, Annals of
Neurology 1990
Effective Fernandez et al. (2012) and Melin et al. (2012)
Moderately effective Zajicek et al. (2003)
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and increased adaptive antiviral CD4, CD8 and Ab immune
responses (Richards et al., 2011). These ﬁndings indicate that
Tregs may control genetic susceptibility to infection-induced
autoimmune disease and provide a novel potential mechanism to
explain the induction of a variety of human autoimmune diseases
secondary to viral or bacterial infection. The preferential expansion
of Tregs in TMEV-infected SJL/J mice, as compared with disease-
resistant C57BL/6 mice, suggests that in some instances, genetic
susceptibility to certain autoimmune diseases may occur due to
‘regulatory mimicry’. In such a scenario a clonotype of nTregs
expressing a self-antigen-speciﬁc T cell receptor on a particular
MHC background could be activated and expand in response to a
cross-reactive epitope expressed by an infectious agent. This
expanded population of Tregs could then delay the clearance of the
infectious agent in the target organ of the immune-mediated
disease, promoting the development of autoimmunity via mecha-
nisms such as molecular mimicry or epitope spreading.
In summary, although the TMEV-IDD model presents both
advantages and disadvantages, it is undoubtedly a valid model for
preclinical studies of MS. This model allows the initial viral
exposure and clearance to be analyzed, as well as the progression
from immune system viral recognition to autoimmunity. The
attack and destruction of axons by CD8+ T cells has been
demonstrated using the TMEV model and there is strong
circumstantial evidence suggesting that a similar process occurs
in MS. Moreover, axonal injury may precede demyelination
following TMEV infection, resulting in the release of neuroantigens
and the induction of autoimmune responses. As such, the TMEV-
IDD model provides a highly useful tool to determine whether
axonal degeneration itself can contribute to secondary neuro-
pathologies, as suggested for MS. Both the EAE and TMEV models
have proven useful in the development of clinical therapies for MS,
and further integration of these models will help advance our
understanding of the etiology and treatment of MS.
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